Announcements Trials
Browse Landscape

Status

Completed 1050Recruiting 362Terminated 276Unknown 264Active not recruiting 152Withdrawn 101Not yet recruiting 79Suspended 13Enrolling by invitation 13Available 2No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Multiple Myeloma 20Melanoma 16Prostatic Neoplasms 15Neoplasms 15Recurrence 13Carcinoma, Non-Small-Cell Lung 13Leukemia, Myeloid, Acute 12Glioblastoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Glioma 7Breast Neoplasms 7Sarcoma 6Neuroblastoma 6Lung Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Lambert-Eaton Myasthenic Syndrome 5Gastrointestinal Stromal Tumors 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neuroendocrine Tumors 4Liver Neoplasms 4Hodgkin Disease 4Precancerous Conditions 3Pheochromocytoma 3

Interventions

tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Brain Neoplasms × Clear all
NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡